Patents by Inventor Angela Mackay

Angela Mackay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220251067
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Application
    Filed: January 13, 2022
    Publication date: August 11, 2022
    Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nichola SMITH, Catherine Fooks SOLOVAY, Nikolaus Johannes STIEFL, Eric VANGREVELINGHE, Juraj VELCICKY, Anette von MATT
  • Patent number: 11254653
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: February 22, 2022
    Assignee: Novartis AG
    Inventors: Christopher Farady, Nina Gommermann, Philipp Janser, Angela Mackay, Henri Mattes, Nichola Smith, Catherine Fooks Solovay, Nikolaus Johannes Stiefl, Eric Vangrevelinghe, Juraj Velcicky, Anette von Matt
  • Patent number: 11208399
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: December 28, 2021
    Assignee: Novartis AG
    Inventors: Christopher Farady, Nina Gommermann, Philipp Janser, Angela Mackay, Henri Mattes, Nichola Smith, Catherine Fooks Solovay, Nikolaus Johannes Stiefl, Eric Vangrevelinghe, Juraj Velcicky, Anette von Matt
  • Publication number: 20210308140
    Abstract: The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R1, R2 and R3 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of disease and disorders mediated by NLRP3.
    Type: Application
    Filed: July 23, 2019
    Publication date: October 7, 2021
    Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nikolaus Johannes STIEFL, Juraj VELCICKY
  • Publication number: 20200361898
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Application
    Filed: May 15, 2020
    Publication date: November 19, 2020
    Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nichola SMITH, Catherine Fooks SOLOVAY, Nikolaus Johannes STIEFL, Eric VANGREVELINGHE, Juraj VELCICKY, Anette von MATT
  • Publication number: 20200361899
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Application
    Filed: May 15, 2020
    Publication date: November 19, 2020
    Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nichola SMITH, Catherine Fooks SOLOVAY, Nikolaus Johannes STIEFL, Eric VANGREVELINGHE, Juraj VELCICKY, Anette von MATT
  • Patent number: 7989438
    Abstract: A class of macrocyclic compounds of formula (I), wherein R7, A, Ar, B, D, F, M, Q1, Q2, W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: August 2, 2011
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Immacolata Conte, Joerg Habermann, Angela Mackay, Frank Narjes, Maria del Rosario Rico Ferreira, Ian Stansfield
  • Publication number: 20090048239
    Abstract: A class of macrocyclic compounds of formula (I), wherein R7, A, Ar, B, D, F, M, Q1, Q2, W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.
    Type: Application
    Filed: July 15, 2008
    Publication date: February 19, 2009
    Inventors: Immacolata Conte, Joerg Habermann, Angela Mackay, Frank Narjes, Maria del Rosario Rico Ferreira, Ian Stansfield